Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese Updated Monday, September 26, 2016
 Services
Submit a manuscript
Subscribe
Individuals
Institutions
Response
Send response
Read responses
Reprint
Advance online publication
Sign up for e-alert
JCIM job opportunities
Contact JCIM
 Information For
Readers
Authors
Reviewers
Advertisers
 About JCIM
Journal description
Editorial policy
Privacy policy
Copy right
Editorial staff
 Language Polishing
Journal of Chinese Integrative Medicine: 2011; 9(1): 38-48
DOI: 10.3736/jcim20110108
Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi
1. Ming-wei Huang (Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fujian Provincial Cardiovascular Disease Institute, Fuzhou 350001, Fujian Province, China )
2. Huan Wang (Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fujian Provincial Cardiovascular Disease Institute, Fuzhou 350001, Fujian Province, China )
3. Wen-juan Zhong (Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fujian Provincial Cardiovascular Disease Institute, Fuzhou 350001, Fujian Province, China )
4. Xiao-ying Wu (Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fujian Provincial Cardiovascular Disease Institute, Fuzhou 350001, Fujian Province, China )
5. Hui Chen (Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fujian Provincial Cardiovascular Disease Institute, Fuzhou 350001, Fujian Province, China )

Objective: In the present study, the efficacy of Naoxintong capsule (NXT), a compound Chinese herbal medicine, combined with dual antiplatelet therapy (DA) in a rat model of coronary microembolization (CME) was evaluated.
Methods: CME in rats was developed by injecting a suspension of microthrombotic particles into the left ventricle when the ascending aorta was obstructed. Microthrombotic particles were generated from the clots of rats sized by filtration through a screen (aperture diameter, 38 μm). A total of 95 rats were randomly divided into six groups, including control group, sham-operation (sham) group, CME model (CME) group, and NXT, DA, and NDA (NXT plus DA) groups. Rats in treatment groups were administered intragastrically with NXT, DA, and NDA, respectively, from 3 d before to 7 d after operation. All rats were sacrificed on day 7 post-operationally, and samples of blood and heart were collected. The complete data of 69 rats were obtained. The incidence of CME (CME%) was evaluated by hematoxylin-eosin staining. Bleeding time (BT) and clotting time (CT) were measured by means of tail cutting and glass slide methods, respectively. Adenosine diphosphate-induced maximum platelet aggregation rate (PAR) was assessed with turbidimetry. Platelet counts were examined by an automated hematology analyzer. The levels of serum P-selectin, interleukin (IL)-6, IL-10, endothelin (ET-1) and endothelial nitric oxide synthase (eNOS) were all detected by enzyme-linked immunosorbent assay.
Results: Compared with control and sham groups, CME group had an increase in CME%, PAR, P-selectin, IL-6 and ET-1 (P<0.01, P<0.01), and a decrease in BT, CT, IL-10 and eNOS (P<0.01, P<0.01); compared with CME group, the groups receiving medications had an increase in BT, CT, IL-10 and eNOS (P<0.05 or P<0.01), and a decrease in CME%, PAR, P-selectin, IL-6 and ET-1 (P<0.05 or P<0.01), with DA group increasing most in BT and CT and decreasing most in PAR and P-selectin, and with NDA group increasing most in IL-10 and eNOS and decreasing most in CME%, IL-6 and ET-1. In terms of platelet counts, there was no statistically significant difference among groups (P>0.05).
Conclusion: NXT combined with DA can decrease CME%. The probable mechanism is that this therapy can appropriately inhibit platelet aggregation, balance the pro- and anti-inflammatory cytokines as well as serum ET-1 and eNOS. This therapy can also reduce risk of intraoperative bleeding during DA therapy.

Welcome to JCIM! You are the number 19328 reader of this article!
Download Article:
[Full Text]      [PDF]      [Chinese]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Huang MW, Wang H, Zhong WJ, Wu XY, Chen H. Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi. J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. 2011; 9(1): 38-48.
References:
1Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization[J].N Engl J Med, 2002, 346(23): 1773-1780.  .
2Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med, 2003, 349(14): 1315-1323.  .
3Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious[J].Circulation, 2004, 109(6): 701-705.  .
4Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern[J].Circulation, 2007, 115(11): 1440-1455.  .
5Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study[J].Lancet, 2007, 369(9562): 667-678.  .
6Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study[J].J Am Coll Cardiol, 2008, 52(14): 1134-1140.  .
7Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J].N Engl J Med, 2001, 345(7): 494-502.  .
8Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J].Lancet, 2001, 358(9281): 527-533.  .
9Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, Pathak A. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients[J].Am J Cardiovasc Drugs, 2010, 10(1): 29-35.  .
10Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schmig A, von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement[J].J Thromb Haemost, 2010, 8(2): 250-256.  .
11Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonzalez MA, Gaglia MA Jr, Xue Z, Kaneshige K, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents[J].Am Heart J, 2010, 159(5): 871-875.  .
12Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, Chan E, Bousser MG, Xuemin S. Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery[J].Stroke, 2009, 40(3): 859-863.  .
13Chen DK, Zhang HQ, Zhang JH. Intervening effect of Naoxintong on anti-platelet treatment with aspirin[J].Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008, 28(9): 843-846. Chinese with abstract in English.
14World Medical Association, American Physiological Society. Guiding principles for research involving animals and human beings[J].Am J Physiol Regul Integr Comp Physiol, 2002, 283(2): R281-R283.  .
15Kudo M, Aoyama A, Ichimori S, Fukunaga N. An animal model of cerebral infarction. Homologous blood clot emboli in rats[J].Stroke, 1982, 13(4): 505-508.  .
16Li S, Zhong S, Zeng K, Luo Y, Zhang F, Sun X, Chen L. Blockade of NF-κB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats[J].Basic Res Cardiol, 2010, 105(1): 139-150.  .
17Erbel R, Heusch G. Coronary microembolization[J].J Am Coll Cardiol, 2000, 36(1): 22-24.  .
18Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease[J].Circulation, 2000, 101(5): 570-580.  .
19Herrmann J. Peri-procedural myocardial injury: 2005 update[J].Eur Heart J, 2005, 26(23): 2493-2519.  .
20Galiuto L, Garramone B, Burzotta F, Lombardo A, Barchetta S, Rebuzzi AG, Crea F; REMEDIA Investigators. Thrombus aspiration reduces microvascular obstruction after primary coronary intervention: a myocardial contrast echocardiography substudy of the REMEDIA Trial[J].J Am Coll Cardiol, 2006, 48(7): 1355-1360.  .
21Srinivasan M, Rihal C, Holmes DR, Prasad A. Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: impact on microvascular perfusion and outcomes[J].Circulation, 2009, 119(9): 1311-1319.  .
22Heusch G, Schulz R, Haude M, Erbel R. Coronary microembolization[J].J Mol Cell Cardiol, 2004, 37(1): 23-31.  .
23Lee KW, Norell MS. Management of ‘no-reflow’ complicating reperfusion therapy[J].Acute Card Care, 2008, 10(1): 5-14.  .
24Pasceri V, Patti G, Di Sciascio G. Prevention of myocardial damage during coronary intervention[J].Cardiovasc Hematol Disord Drug Targets, 2006, 6(2): 77-83.  .
25Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death[J].Circulation, 1986, 73(3): 418-427.  .
26Valero SJ, Moreno R, Reyes RM, Recalde AS, Galeote G, Calvo L, Villate A, Sendón JL. Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions[J].Cardiovasc Hematol Agents Med Chem, 2008, 6(2): 125-129.  .
27Ivandic BT, Sausemuth M, Ibrahim H, Giannitsis E, Gawaz M, Katus HA. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention[J].Clin Chem, 2009, 55(6): 1171-1176.  .
28Xing YN, Yang GJ, Liu SN, Wu B, Xu N. The research outline of blood stasis syndrome in coronary heart disease[J].Zhongguo Yi Yao Dao Bao, 2009, 6(2): 5-6. Chinese.
29Praticò D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice[J].Proc Natl Acad Sci U S A, 2001, 98(6): 3358-3363.  .
30Ruggeri ZM. Platelets in atherothrombosis[J].Nat Med, 2002, 8(11): 1227-1234.  .
31Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — Ⅰ: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients[J].BMJ, 1994, 308(6921): 81-106.  .
32Lardizabal JA, Joshi BK, Ambrose JA. The balance between anti-ischemic efficacy and bleeding risk of antithrombotic therapy in percutaneous coronary intervention: a yin-yang paradigm[J].J Invasive Cardiol, 2010, 22(6): 284-292.  .
33Libby P. Vascular biology of atherosclerosis: overview and state of the art[J].Am J Cardiol, 2003, 91(3A): 3A-6A.  .
34Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6[J].Eur Heart J, 2000, 21(19): 1574-1583.  .
35Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link[J].Atherosclerosis, 2000, 148(2): 209-214.  .
36Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI. Interleukin-18︰interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome[J].Atherosclerosis, 2005, 182(1): 135-143.  .
37Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleukin-10 in atherosclerosis[J].Circ Res, 1999, 85(8): e17-e24.  .
38Terkeltaub RA. IL-10: an “immunologic scalpel” for atherosclerosis[J].Arterioscler Thromb Vasc Biol, 1999, 19(12): 2823-2825.  .
39Terkeltaub RA. Libby P, Simon DI[J].Inflammation and thrombosis: the clot thickens, 2001, 103(13): 1718-1720.  .
40Martin DM, Boys CW, Ruf W. Tissue factor: molecular recognition and cofactor function[J].FASEB J, 1995, 9(10): 852-859.  .
41Nachman RL. Thrombosis and atherogenesis: molecular connections[J].Blood, 1992, 79(8): 1897-1906.  .
42Rodgers GM. Hemostatic properties of normal and perturbed vascular cells[J].FASEB J, 1988, 2(2): 116-123.  .
43Zouridakis EG, Schwartzman R, Garcia-Moll X, Cox ID, Fredericks S, Holt DW, Kaski JC. Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression[J].Eur Heart J, 2001, 22(17): 1578-1584.  .
44Rodeberg DA, Chaet MS, Bass RC, Arkovitz MS, Garcia VF. Nitric oxide: an overview[J].Am J Surg, 1995, 170(3): 292-303.  .
45Ulker S, McKeown PP, Bayraktutan U. Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells[J].Cardiovasc Res, 2002, 55(4): 830-837.  .

 Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese
Copyright © 2003-2012 by JCIM Press. All rights reserved. ISSN 1672-1977